Search

Celldex Therapeutics Inc

Closed

SectorHealthcare

29.11 0.55

Overview

Share price change

24h

Current

Min

28.01

Max

29.35

Key metrics

By Trading Economics

Income

5.2M

-74M

Sales

7K

22K

EPS

-0.94

Profit margin

-334,104.545

Employees

198

EBITDA

5.2M

-73M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+126.21% upside

Dividends

By Acuity

Next Earnings

6 Nov 2026

Market Stats

By TradingEconomics

Market Cap

-628M

2.3B

Previous open

28.56

Previous close

29.11

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Oct 2026, 19:56 UTC

Correlated Moves

Shares of Celldex Therapeutics Inc are declining amid negative market reaction to Moderna's cancer vaccine trial results, impacting the SPDR S&P Biotech ETF (XBI).

21 Oct 2026, 19:46 UTC

Celldex Therapeutics Inc shares are declining, having pulled back from earlier gains amid broader market weakness and trading significantly below its 20-day moving average.

20 Oct 2026, 20:31 UTC

Celldex Therapeutics Inc shares are trading lower in after-market hours, shifting from an initial gain to a notable loss since Tuesday's close.

19 Oct 2026, 20:01 UTC

Celldex Therapeutics Inc shares are trading significantly higher, reaching a notable peak late morning before a slight retracement amid recent declines.

16 Oct 2026, 20:01 UTC

Correlated Moves
Social Media

Celldex Therapeutics Inc shares are declining amid a broader downturn in the biotechnology sector, as the SPDR S&P Biotech ETF (XBI) also falls.

15 Oct 2026, 19:26 UTC

Correlated Moves

The SPDR S&P Biotech ETF is trading higher, supported by analyst upgrades for biotech firms, including Goldman Sachs' price target raise for Moderna.

14 Oct 2026, 23:36 UTC

Celldex Therapeutics Inc experienced a modest decline during after-market hours on Wednesday, continuing a pattern of lower daily closes and remaining below its 20-day moving average.

13 Oct 2026, 20:01 UTC

Correlated Moves

Celldex Therapeutics shares are declining, following a brief rebound earlier in the session, as the SPDR S&P Biotech ETF also faces losses.

9 Oct 2026, 19:46 UTC

Correlated Moves

Shares of Celldex Therapeutics Inc are advancing, supported by a rise in the SPDR S&P Biotech ETF following gains from Moderna amid cancer vaccine partnership news.

8 Oct 2026, 20:07 UTC

Celldex Therapeutics Inc shares are declining, reflecting broader market weakness amid significant downturns and ongoing challenges, remaining well below the 20-day moving average.

6 Oct 2026, 20:00 UTC

Correlated Moves

Celldex Therapeutics Inc shares fell amid a broader biotechnology sector decline, influenced by Federal Reserve comments on inflation risks and a widening U.S. trade deficit.

5 Oct 2026, 20:01 UTC

Celldex Therapeutics Inc is advancing, regaining momentum after pulling back earlier, amid unusual strength while trading near the lower end of its one-month range.

2 Oct 2026, 20:00 UTC

Celldex Therapeutics Inc shares fell more than two percent, reversing earlier gains and remaining significantly below its 20-day moving average.

1 Oct 2026, 19:46 UTC

Correlated Moves

Celldex Therapeutics Inc shares fell, continuing a trend from Wednesday, amid a slight downturn in the State Street SPDR S&P Biotech ETF.

30 Sept 2026, 23:45 UTC

Celldex Therapeutics Inc is rising in after-market trading, gaining ground since Wednesday's close, despite remaining below its 20-day moving average.

29 Sept 2026, 19:46 UTC

News

Celldex Therapeutics Inc shares are higher today after positive feedback on Barzolvolimab, with analysts raising the price target to $64 per share.

28 Sept 2026, 22:35 UTC

Celldex Therapeutics Inc is trading modestly higher in after-market hours, recovering from an early dip but remains below its 20-day moving average.

25 Sept 2026, 19:20 UTC

Celldex Therapeutics Inc shares fell sharply after an early high, currently trading below Thursday's close and notably under its 20-day moving average.

23 Sept 2026, 20:02 UTC

News
Social Media

Celldex Therapeutics shares fell sharply amid safety concerns from its Phase 3 CSU study, despite Overweight ratings from Morgan Stanley and Leerink Partners.

22 Sept 2026, 23:06 UTC

Celldex Therapeutics Inc is seeing a modest increase in after-market trading, recovering from an earlier session low and gaining since Tuesday's close.

21 Sept 2026, 20:01 UTC

Celldex Therapeutics Inc shares fell sharply, diverging from recent gains as the biotechnology sector shows varied performance.

18 Sept 2026, 20:02 UTC

Celldex Therapeutics Inc shares fell sharply, remaining well below their 20-day moving average after a notable high earlier in the session.

17 Sept 2026, 20:07 UTC

Correlated Moves

Celldex Therapeutics Inc is modestly higher in Thursday's session, rebounding from an earlier pullback, amid a boost from positive developments in the biotech sector.

16 Sept 2026, 20:10 UTC

Celldex Therapeutics Inc is advancing in Wednesday's market session, showing modest gains since Tuesday, despite pulling back from earlier session highs.

15 Sept 2026, 20:07 UTC

Correlated Moves

Celldex Therapeutics Inc shares are lower amid sector-wide weakness in biotechnology, influenced by rising yields and Federal Reserve concerns.

14 Sept 2026, 20:03 UTC

Celldex Therapeutics Inc shares are higher today, with no specific news identified. Rising crude oil prices contribute to broader market inflation concerns ahead of the Fed's decision.

11 Sept 2026, 20:08 UTC

Celldex Therapeutics Inc shares are lower today, continuing a five-session decline. The stock is trading significantly below its 20-day moving average.

10 Sept 2026, 19:26 UTC

Correlated Moves

Celldex Therapeutics Inc shares are lower, reflecting bearish sentiment in the biotechnology sector. The stock remains below its 20-day moving average.

8 Sept 2026, 20:07 UTC

Celldex Therapeutics Inc shares are lower today, reflecting ongoing performance weakness amid speculation about a potential Federal Reserve interest rate hike.

28 Aug 2026, 20:03 UTC

Celldex Therapeutics Inc. shares are lower today, breaking a trend of higher closes. Broader market conditions may be influencing this shift.

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

126.21% upside

12 Months Forecast

Average 66.167 USD  126.21%

High 100 USD

Low 28 USD

Based on 12 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat